LLY ELI LILLY & Co
Pharmaceutical Preparations · NYSE · SEC CIK 59478 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY45.5%
TTM net income YoY49.8%
TTM EPS YoY50.7%
Revenue 3-yr CAGR39.2%
Net income 3-yr CAGR76.8%
Margins
Gross margin83.6%
Operating margin—
Net margin31.9%
FCF margin—
EBITDA margin—
Returns
ROE86.1%
ROA21.0%
ROIC (approx.)—
Asset turnover0.66x
Leverage & solvency
Liabilities / assets72.8%
Debt / equity1.23x
Current ratio1.39x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.11x
Accruals ratio-2.3%
Payout ratio21.7%
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $65.18B | $45.04B |
| Cost of revenue | $11.05B | $8.42B |
| Gross profit | $54.13B | $36.62B |
| R&D expense | $13.34B | $10.99B |
| SG&A expense | $11.09B | $8.59B |
| Interest expense | $895.00M | $781.00M |
| Pretax income | $25.73B | $12.68B |
| Income tax | $5.09B | $2.09B |
| Net income | $20.64B | $10.59B |
| EPS (basic) | 23.00 | 11.76 |
| EPS (diluted) | 22.95 | 11.71 |
| Dividends declared per share | 6.23 | 5.40 |
| Weighted avg. shares (diluted) | 899.30M | 904.10M |
| Balance sheet | ||
| Cash & equivalents | $7.27B | $3.27B |
| Short-term investments | — | $154.80M |
| Receivables | $17.76B | $11.01B |
| Inventory | $13.74B | $7.59B |
| Current assets | $55.63B | $32.74B |
| PP&E, net | $24.68B | $17.10B |
| Goodwill | $5.90B | $5.77B |
| Intangibles | $6.52B | $6.17B |
| Total assets | $112.48B | $78.72B |
| Current liabilities | $35.23B | $28.38B |
| Short-term debt | $1.64B | $5.12B |
| Long-term debt | $40.87B | $28.53B |
| Total debt | $42.50B | $33.64B |
| Total liabilities | $85.94B | $64.44B |
| Shareholders' equity | $26.54B | $14.27B |
| Net debt | $35.23B | $30.38B |
| Cash flow statement | ||
| Operating cash flow | $16.81B | $8.82B |
| Investing cash flow | -$10.97B | -$9.30B |
| Financing cash flow | -$2.21B | $1.23B |
| Depreciation & amortization | $2.00B | $1.77B |
| Stock-based compensation | $626.00M | $646.00M |
| Dividends paid | $5.38B | $4.68B |
| Share buybacks | $4.11B | $2.50B |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.